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Beta-agonist overuse and delay in obtaining medical review
in high risk asthma: a secondary analysis of data from a
randomised controlled trial
Janine Pilcher1,2, Mitesh Patel1,3,4, Alison Pritchard1, Darmiga Thayabaran1,2, Stefan Ebmeier1,2, Dominick Shaw 3, Peter Black5,
Irene Braithwaite 1, Mark Weatherall2,6 and Richard Beasley1,2,6
Asthma mortality surveys report delays in seeking medical review and overuse of beta-agonist therapy as factors contributing to a
fatal outcome. However, the strength of these associations is limited because many asthma deaths are unwitnessed. We undertook
a secondary analysis of data from a 24-week randomised controlled trial of 303 patients with high-risk asthma, randomised to
combination budesonide/formoterol inhaler according to a single maintenance and reliever therapy regimen or ﬁxed dose
budesonide/formoterol with salbutamol as reliever (Standard) regimen. Medication use was measured by electronic monitors. The
thresholds for high, marked and extreme beta-agonist use days were deﬁned in the single maintenance and reliever therapy arm
as: >8, >12 and >16 actuations of budesonide/formoterol in excess of four maintenance doses, respectively; and in the Standard
arm as: >16, >24 and >32 actuations of salbutamol, respectively. Whether a medical review was obtained within 48 h of an overuse
episode was determined by review of data collected during the study by participant report. The mean (standard deviation)
proportion of days in which high, marked and extreme beta-agonist overuse occurred without medical review within 48 h was 0·94
(0·20), 0·94(0·15) and 0·94(0·17), and 0·92(0·19), 0·90(0·26) and 0·94(0·15) for single maintenance and reliever therapy and Standard
regimens, respectively. In at least 90% of days, in which beta-agonist overuse occurred, patients did not obtain medical review
within 48 h of beta-agonist overuse, regardless of the magnitude of overuse or the inhaled corticosteroid/long-acting beta-agonist
regimen.
npj Primary Care Respiratory Medicine  (2017) 27:33 ; doi:10.1038/s41533-017-0032-z
INTRODUCTION
Asthma mortality surveys report that delay in seeking medical
review is a common and important factor contributing to a fatal
outcome.1–5 Beta-agonist overuse immediately before asthma
death has also been reported, but the strength of this association
is limited because these surveys rely on reports from relatives and
friends of patients who have died from asthma.1–5 Furthermore,
many asthma deaths are unwitnessed. Prescription database
surveys identify a strong association between increased dispensing
of short-acting beta-agonist drugs and the risk of mortality.6–10
The risk of asthma death increases markedly when more than 1.4
inhaler canisters per month are dispensed.7 Although this is
estimated to be equivalent to an average of ten actuations
per day, this may not correspond to actual patterns of use during
a severe exacerbation. Patients with asthma also often report
taking very high doses of beta-agonists during severe exacerba-
tions leading to hospital admission, but these estimates may be
inﬂuenced by recall bias.11 In the situation of stable asthma,
patients who overuse their medications are likely to under-report
actual use and conversely those who underuse tend to over-report
actual use.12
The best method to assess actual patient self-administration of
beta-agonist is to use validated electronic monitors that record
the exact date and time of each actuation.13, 14 This approach has
been used in one 13-week observational study in children15 and
also in one 24-week randomised controlled trial (RCT) of two
regimens based on maintenance combination budesonide/for-
moterol inhaler therapy in high risk adult asthma.16 In this RCT, we
reported long-term patterns of beta-agonist use16 as well as use
during severe exacerbations leading to hospital attendance.17 We
identiﬁed that in less than 10% of days when high beta-agonist
use occurred, deﬁned as > 16 actuations of salbutamol (or
equivalent) in a 24-h period, did patients obtain medical review
within 48 h, despite this advice being verbally explained and
documented in the asthma action plans provided.16 About one in
four patients self-administered >32 actuations per day of
salbutamol (or equivalent) on at least one occasion during the
study. These ﬁndings showed the extent of unsupervised beta-
agonist overuse by patients at risk of severe asthma exacerbations.
In a subsequent analysis, we identiﬁed that very high doses of
beta-agonist were commonly self-administered by patients with-
out seeking medical review within 2 weeks before hospital
presentation with a severe exacerbation of asthma.17
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The objectives of this current analysis were to investigate the
incidence of delay in obtaining medical review at different levels
of excessive beta-agonist use throughout the 24 weeks of the RCT,
and to describe patterns of beta-agonist use before and after
severe exacerbations requiring systemic corticosteroid therapy.
Our hypothesis was that most episodes of beta-agonist use, in
excess of the thresholds at which medical review was recom-
mended in the implemented asthma action plans, would not
result in patients obtaining medical care.
RESULTS
The participants in the RCT are described in Table 1. There were
151 participants randomised to the single maintenance and
reliever therapy (SMART) regimen and 152 participants to the
Standard regimen.
High, marked and extreme beta-agonist use episodes without
medical review within 48 h
The proportions of participants with at least one high, marked and
extreme use episode were similar in each regimen (Tables 2a–c,
respectively). The total number of days of high, marked and
extreme use were greater in the Standard regimen (Tables 2a–c,
respectively).
In the SMART regimen, the number of high use days without
medical review within 48 h was approximately half of that in the
Standard regimen; relative rate (95% CI) 0·49 (0·31 to 0·75),
P = 0·001 (Fig. 1, Table 2a). The point estimate of association was
consistent with a lower number of marked and extreme use days
without medical review within 48 h with the SMART regimen
(Fig. 1 and Tables 2b, 2c, respectively).
In both the SMART and Standard regimens, the proportion of
high, marked and extreme use days without medical review within
48 h, compared to total days of high, marked and extreme use was
at least 90% (Tables 2a, 2b and 2c, respectively).
Severe exacerbations of asthma
During the study period, at least one severe asthma exacerbation
was experienced by 28/151 (18·5%) of SMART participants and
50/152 (32·9%) of Standard participants. There was a total of 35 and
66 severe exacerbations in the SMART and Standard groups
respectively; relative rate (95% CI) 0·54 (0·36 to 0·82), P = 0·004.
Daily medication use prior to and following severe exacerbations
Medication use in the 14 days prior to and 14 days following a
severe exacerbation for the SMART and Standard regimens is
shown in Figs. 2 and 3, respectively. With the SMART regimen,
there was increasing budesonide/formoterol use from about
5 days prior to initiation of oral corticosteroid therapy, with high
use for a further 5 days before returning to baseline levels after
10 days. With the Standard regimen, there was variable
salbutamol use from about 14 days prior to initiation of oral
corticosteroid therapy, increasing markedly the day before,
with high use for a further 3 days before returning to baseline
levels after 10 days. In the severe exacerbation dataset, only one of
the included days, 2 days prior to severe exacerbation for a patient
in the Standard group, met dose dumping criteria, deﬁned as
greater than or equal to 100 actuations in a 3-h period.18
The number of days in which high, marked or extreme use
occurred in the 14 days prior to a severe exacerbation, expressed
as a percentage of all high, marked and extreme use days was 56/
766 (7%), 28/400 (7%) and 10/237 (4%) for SMART, and 166/1355
(12%), 111/735 (15%) and 80/438 (18%) for Standard, respectively.
Of the high use episodes in the 14-day period prior to a severe
exacerbation, 38/56 (68%) and 133/166 (80%) were not associated
with medical review within 48 h, in the SMART and Standard
regimens, respectively. Of the marked overuse episodes in the
14-day period prior to a severe exacerbation, 18/28 (64%) and
87/111 (78%) were not associated with medical review within 48 h,
in the SMART and Standard regimens, respectively. Finally, of the
extreme overuse episodes in the 14-day period prior to a severe
exacerbation, 5/10 (50%) and 65/80 (81%) were not associated
with medical review within 48 h, in the SMART and Standard
regimens, respectively.
Table 1. Participant characteristics
Characteristic SMART group
(N= 151)
Standard group
(N= 152)
Mean [(standard deviation (SD)]
Age (years) 41·3 (13·7) 42·6 (14·5)
ACQ-5 Score 1·78 (0·99) 1·79 (2·4)
Daily ICS dose (budesonide
or equivalent), µg
805 (353) 813 (370)
On-treatment FEV1 (L) 2·62 (0·91) 2·50 (0·78)
On-treatment FEV1 %
predicted
81·6 (18·9) 80·4 (20·5)
Severe exacerbations in the
prior 12 months
1·55 (1·31) 1·73 (1·22)
Median (IQR)
Baseline self-reported
reliever usea
2 (1 to 3) 2 (1 to 3)
Number of hospital
admissions ever for asthma
1 (0 to 4) 1 (0 to 4)
N/151 (%) N/152 (%)
Male 48 (31·8) 46 (30·3)
Ethnicity
European 113 (74·8) 118 (77·6)
Māori 25 (16·6) 19 (12·5)
Paciﬁc Islander 5 (3·3) 10 (6·6)
Other 8 (5·3) 5 (3·3)
Number of severe exacerbations in previous 12 months
0 14 (9·3) 11 (7·2)
1 86 (57·0) 75 (49·3)
2 29 (19·2) 31 (20·4)
3 10 (6·6) 22 (14·5)
4 5 (3·3) 6 (3·9)
≥5 7 (4·6) 7 (4·6)
LABA use 92 (60·9) 103 (67·8)
Combination ICS plus LABA
inhaler
73 (48%) 82 (54%)
Use of written asthma self-
management plan
15 (10%) 20 (13%)
Current smokers 30 (19·9) 29 (19·1)
Ex-smokers 49 (32·5) 48 (31·6)
Non-smokers 72 (47·7) 75 (49·3)
ACQ asthma control questionnaire, FEV1 forced expiratory volume in one
second, ICS inhaled corticosteroids, LABA long acting beta-agonist
a As per the ACQ question 6. ACQ question 6 is a categorical score of beta-
agonist use over the preceding 7 days in the following bands: score 0—
none; score 1—1 to 2 salbutamol inhalations most days; score 2—3 to
4 salbutamol inhalations most days; score 3—5 to 8 salbutamol inhalations
most days; score 4—9 to 12 salbutamol inhalations most days; score 5—13
to 16 salbutamol inhalations most days; score 6—more than 16 salbutamol
inhalations most days.
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Highest medication use prior to and following severe
exacerbations
In the SMART group, the median (range) highest daily number of
budesonide/formoterol actuations was 11 (4 to 63) over the
14 days before severe exacerbations. In the Standard group, the
median (range) highest daily number of salbutamol actuations
was 13 (0 to 150) over the 14 days before severe exacerbations; on
the day of highest salbutamol use preceding severe exacerbations,
the median (range) number of budesonide/formoterol actuations
was 4 (0 to 84). On this day of maximal salbutamol use, there
were 8/61 (13%) instances when >8 actuations of budesonide/
formoterol were taken and 10/61 (16%) instances when zero
actuations of budesonide/formoterol were taken.
In the SMART group, the median (range) highest daily number
of budesonide/formoterol actuations was 10 (0 to 71) in the
14 days after oral corticosteroid use for severe exacerbations (Day
0). In the Standard group, the median (range) highest daily
number of salbutamol actuations was 20 (0 to 152) in the 14 days
after Day 0; on the day of highest salbutamol use following Day 0,
the median (range) number of budesonide/formoterol actuations
was 4 (0 to 33). On this day of maximal salbutamol use, there were
7/61 (11%) instances when >8 actuations of budesonide/
formoterol were taken and 9/61 (15%) instances when zero
actuations of budesonide/formoterol were taken.
DISCUSSION
This study shows that in a high-risk population of adult patients
with asthma, around 90% of beta-agonist overuse episodes, well
in excess of the asthma action plan thresholds recommending
prompt medical review, do not lead to patients obtaining medical
review within 48 h. It is likely that the symptomatic relief obtained
from the high doses of beta-agonist may be one of the underlying
causes for the delay in or lack of seeking medical help in the
situation of such poorly controlled, worsening asthma.
We observed that in around 90% of marked and extreme
overuse episodes, patients did not obtain medical review within
48 h despite this use being at least 1·5 and 2-fold higher than the
level of use at which their asthma action plan advised that medical
care must be sought. These ﬁndings complement our previous
observation that 93% of high-use episodes, in which patients took
at least 16 actuations of salbutamol or equivalent in a 24-h period,
occurred without medical review within the next 48 h, despite this
advice being documented in the provided asthma action plans.16
These ﬁndings were unexpected as they suggest that increasing
beta-agonist use from at least 16 to at least 32 actuations of
salbutamol or equivalent in a 24-h period did not lead to a greater
likelihood of a patient seeking medical care.
Patterns of beta-agonist use were also examined in the patients
in whom a severe exacerbation was conﬁrmed with the
prescription of systemic corticosteroids. In the SMART regimen,
the mean daily use of budesonide/formoterol progressively
increased 5 days before the index corticosteroid use and remained
high for a further 5-day period before returning close to baseline
levels after 10 days. For the Standard regimen, the salbutamol use
was variable from about 14 days prior to the index course of
corticosteroids, increasing markedly the day before, with the high
level of use gradually returning to baseline levels over 10 days.
The majority of overuse episodes in the 14-day period prior to the
initiation of oral corticosteroid therapy were not associated with
medical review within 48 h, regardless of the magnitude of the
overuse. These ﬁndings suggest that even in patients who did
seek medical review, there is often delay during worsening
asthma, resulting in the later prescription of oral corticosteroids in
a severe exacerbation. This may have contributed to our ﬁnding
that in the setting of a severe exacerbation it takes at least 5 days
of oral corticosteroid treatment before there is sufﬁcientT
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improvement to result in a reduction in beta-agonist use,
regardless of whether the SMART or Standard regimen was used.
Different patterns of budesonide/formoterol use were observed
in the Standard group during severe exacerbations. Some patients
used no budesonide/formoterol on the day of highest salbutamol
use preceding the severe exacerbation. This non-adherence may
contribute to progressive worsening of unstable asthma, increas-
ing the risk of a severe exacerbation. Another pattern was the use
of budesonide/formoterol as an as required ‘reliever’ medication
well in excess of the maintenance four actuations per day. These
observations suggest that some patients may use their main-
tenance budesonide/ formoterol inhaler according to presumed
need, similar to the SMART regimen, despite being prescribed
ﬁxed dose maintenance treatment and salbutamol for reliever.
Another important observation was that while the SMART
regimen reduced the number of high, marked and extreme
overuse episodes by at least 40%, it did not inﬂuence the
likelihood of a patient obtaining medical review when an overuse
episode occurred. As a result, the SMART regimen reduced the
total number of overuse episodes in which patients did not obtain
medical review within 48 h, to a similar extent to which it reduced
the total number of overuse episodes. Together with the 46%
reduction in severe exacerbations, these ﬁndings suggest that the
SMART regimen has a better safety proﬁle as it reduced the total
number of overuse episodes in which delay in obtaining medical
review occurred.
There are a number of methodological issues that require
consideration. As an open-label study, there was the potential for
bias, however the use of a single inhaler in the SMART regimen
and separate inhalers in the Standard regimen without the
requirement for dummy placebo inhalers enhanced generalisa-
bility of the ﬁndings to real world clinical practice. Metered dose
inhaler (MDI)’s were used rather than dry powder inhalers
(Turbuhaler) to deliver budesonide/formoterol, as it enabled us to
Fig. 2 Median [interquartile range (IQR)] daily budesonide/formoterol actuations in the 14 days prior to, and the 14 days following a severe
exacerbation in the SMART group. Day 0 represents the initiation of corticosteroid therapy. There were 35 severe exacerbations in the SMART
group. For patients with repeat exacerbations, a minimal interval of 28 days between exacerbations was required, to avoid overlap of data
within the same participant. One patient in the SMART group had a second severe exacerbation within 28 days following the prior
exacerbation. Thus, electronic data for 34 severe exacerbations were included in the plots of medication use patterns for the SMART group
Fig. 1 a Mean number of high use days in participants with at least one high use episode, and mean number of high use days without
medical review within 48 h in participants with at least one high use episode. b Mean number of marked overuse days in participants with at
least one marked overuse episode, and mean number of marked overuse days without medical review within 48 h in participants with at least
one marked overuse episode. c Mean number of extreme overuse days in participants with at least one extreme overuse episode, and mean
number of extreme overuse days without medical review within 48 h in participants with at least one extreme overuse episode
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Fig. 3 Median (IQR) daily salbutamol a and budesonide/formoterol b actuations in the 14 days prior to, and the 14 days following a severe
exacerbation in the Standard group. Day 0 represents the initiation of corticosteroid therapy. There were 66 severe exacerbations in the
Standard group. For patients with repeat exacerbations, a minimal interval of 28 days between exacerbations was required, to avoid overlap of
data within the same participant. Three patients in the Standard group had repeat severe exacerbations occurring within 28 days following
the prior exacerbation. In another patient randomised to Standard treatment, there was no recorded data for two severe exacerbations due to
use of non-study inhaled medication. Thus, electronic data for 61 severe exacerbations were included in the plots of medication use patterns
in the Standard group. For these plots, only one of the included days (2 days prior to severe exacerbation for a patient in the Standard group)
met dose dumping criteria (≥100 actuations in a 3 h period)
Beta-agonist overuse and delay in medical review in asthma exacerbations
J Pilcher et al.
6
npj Primary Care Respiratory Medicine (2017)  33 Published in partnership with Primary Care Respiratory Society UK
use validated electronic monitors of inhaler use.19, 20 Beta-agonist
overuse related to the measures of budesonide/formoterol and
salbutamol for the SMART and Standard regimens, respectively. This
is likely to have led to an underestimation of the number of beta-
agonist overuse episodes for the Standard regimen, as it did not
take into account the use of budesonide/formoterol as a reliever
additional to the four maintenance actuations per day, a behaviour
which was noted in some patients.17
There are several additional clinical implications of these
ﬁndings. Firstly, the patient’s failure to recognise that the need
for frequent and high doses of beta-agonist indicates severe
asthma, likely contributes to the delay in or lack of seeking
medical help. Secondly, this behaviour may reﬂect previous
experience of these high risk patients with asthma, that most
exacerbations of asthma requiring high doses of beta-agonist are
self-limiting and eventually resolve without medical review, oral
corticosteroids, or hospital attendance. This interpretation is
supported by our observation that over 80% of all days of beta-
agonist overuse, regardless of extent, did not lead to a course of
oral steroids within the following 14 days. The higher proportions
associated with the SMART regimen suggest that budesonide/
formoterol overuse may be more likely to lead to resolution of the
severe asthma episode without oral steroids than salbutamol
overuse. Thirdly, even in the setting of an RCT with repeat clinic
visits during which the asthma action plan was introduced and
reinforced, most patients did not follow this written advice
to obtain medical review when beta agonist use exceeded
predeﬁned levels of increased use.
In conclusion, in at least 90% of days in which beta-agonist
overuse occurred, patients with high-risk asthma did not obtain
medical review within 48 h, regardless of the magnitude of the
beta-agonist overuse, or the inhaled corticosteroid/long-acting
beta-agonist regimen.
METHODS
Design
This is a secondary analysis of data from a 24-week multicentre, open-label
RCT of Single combination budesonide/formoterol inhaler as Maintenance
And Reliever Therapy (SMART regimen) vs. ﬁxed-dose budesonide/
formoterol with salbutamol for relief (Standard regimen) in 303 adult
patients with a physician’s diagnosis of asthma, described previously.16
Patients were eligible if they had a current prescription for inhaled
corticosteroids (ICS) and at least one asthma exacerbation in the preceding
year. An exacerbation was deﬁned as presentation to a General Practice or
Emergency Department resulting in prescription of oral corticosteroids or
treatment with spacer-delivered or nebulised bronchodilator, or self-
administration of prednisone for asthma for at least 3 days. Exclusion
criteria included a diagnosis of chronic obstructive pulmonary disease and
current or ex-smokers with a > 10 pack-year smoking history with onset of
respiratory symptoms after the age of 40.
Patients were randomised to the SMART regimen: a MDI containing 200/
6 µg budesonide/formoterol (Vannair, AstraZeneca Limited, Auckland, New
Zealand, which is the MDI formulation of Symbicort turbuhaler), two
actuations twice daily for maintenance with one extra dose as needed for
relief; or the Standard regimen: 200/6 µg Vannair MDI, two actuations twice
daily for maintenance with 100 µg salbutamol MDI (Ventolin, GlaxoSmithK-
line Limited, Auckland, New Zealand), one to two extra actuations for relief.
All participants were given written asthma action plans and verbal
instructions outlining when to consult their doctor. All participants
provided written informed consent and the trial was approved by the
New Zealand Multi Region Ethics Committee, and prospectively registered
[ACTRN 12610000515099]. The study protocol is available at http://www.
mrinz.ac.nz/uploads/mrinz/SMART_Protocol.pdf
All Vannair and Ventolin MDIs incorporated an electronic monitor
(Smartinhaler Tracker, Nexus6 Limited, Auckland, New Zealand), which
recorded the date and time (to the nearest second) each time an inhaler
was actuated. These monitors were 99·7% accurate in recording actuations
in bench testing19 and were used in accordance with strict trial quality
control processes.20 Participants were not aware of the exact capabilities of
the monitors.
Deﬁnitions of high, marked and extreme beta-agonist use
episodes
High use. For SMART, this was deﬁned as >8 actuations of budesonide/
formoterol in excess of the four maintenance doses per 24-h period i.e.,
equivalent to >12 actuations in total. For Standard, this was deﬁned as >16
actuations of salbutamol per 24-h period. These thresholds were based on
the dose limits of beta-agonist use requiring medical review, deﬁned by
the action plans implemented in this study,21, 22 and supported by the
results of the short-term bronchodilator equivalence of formoterol 6 µg to
salbutamol 200 µg, with repeat dosing in acute asthma.23, 24 In accordance
with their action plans, participants were advised to seek medical review at
these high use thresholds.
Marked use. For SMART, this was deﬁned as >12 actuations of
budesonide/formoterol in excess of the four maintenance doses per 24-
h period i.e., equivalent to >16 actuations in total. For Standard, this was
deﬁned as >24 actuations of salbutamol per 24-h period. These thresholds
were based on 1.5 times the limits of beta-agonist use requiring medical
review, deﬁned by the action plans.21, 22
Extreme use. For SMART, this was deﬁned as >16 actuations of
budesonide/formoterol in excess of the four maintenance doses per
24-h period i.e., equivalent to >20 actuations in total. For Standard, this was
deﬁned as >32 actuations of salbutamol per 24-h period. These thresholds
were based on twice the limits of beta-agonist use requiring medical
review, deﬁned by the action plans.21, 22
High, marked, and extreme beta-agonist use without medical
review
The number of days of high, marked, or extreme beta-agonist use without
medical review within 48 h was determined using the following rules: for
every high, marked, or extreme beta-agonist use day, the ‘index day’, the
database was checked to determine if the patient attended for medical
review, which could include primary care clinic, an after-hours clinic or
hospital attendance, either on the day of overuse or the next day. This 48-h
window was deﬁned as per the Standard action plan, which speciﬁes that
the patient should attend for medical review ‘within 1 to 2 days’ in the
setting of worsening asthma recognised by symptoms including ‘reliever
only lasting 2–3 h’.22 The SMART plan advises patients to seek medical
review on the same day if more than 12 actuations of budesonide/
formoterol are taken.21
If the participant attended for medical review, then overuse occurring on
the index day, the day of medical review and in the 7 days after medical
review was not counted as overuse without medical review, as a ‘stand-
down’ period. In effect, overuse occurring on these days was ‘permissible’
as the patient had attended for medical review in the setting of this
exacerbation. This criterion was chosen as the american thoracic society
(ATS)/european respiratory society (ERS) deﬁnition of severe exacerbations
separate exacerbations by 7 days.25 If a participant attended for repeated
medical reviews during the stand-down period, then the 7-day period
where overuse without medical review is not counted, was restarted. This
approach was used as the object of this analysis was to explore the
relationship between the ‘index’ overuse episode and the ﬁrst episode of
medical review following this.
Outcomes
In this exploratory analysis, no particular primary outcome was speciﬁed
and there is no adjustment for multiple comparisons. The outcome
variables were ﬁrstly the proportion of participants in each arm of the RCT
with at least one episode of overuse for each type of beta-agonist overuse;
high, marked and extreme. A second outcome was the number of days of
overuse for each type of beta-agonist overuse. A third outcome was the
number of days of overuse without medical review within 48 h for each
type of beta-agonist overuse. The ﬁnal outcome was the proportion of
days of overuse without medical review within 48 h compared to the total
number of days of overuse for each type of beta-agonist overuse.
Medication use in the 14 days prior to and following a severe
exacerbation was also examined. A severe exacerbation was deﬁned
according to ATS/ERS criteria25 as: (a) the use of systemic corticosteroids
for at least 3 days; or (b) a hospitalisation or Emergency Department visit
because of asthma, requiring systemic corticosteroids. Courses of
corticosteroids separated by 7 days or more were treated as separate
severe exacerbations. The date of the ﬁrst day of corticosteroid therapy
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was Day 0. Medication use for the 14-day period before and up to 14 days
after Day 0 was extracted from the data set for each participant with at
least one severe exacerbation. For patients with repeat exacerbations, a
minimum interval of 28 days between exacerbations was required to avoid
overlap of data within the same participants.
Statistical methods
The relative risk of at least one episode of overuse by overuse type was by
simple contingency table analysis and expressed as a relative risk. The
relative rates of days of high, marked and extreme beta-agonist overuse
was by Poisson regression with an offset for the adjusted days of treatment
exposure, and a further adjustment for over-dispersion. SAS version 9·4
was used.
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